Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 3;15:1360281. doi: 10.3389/fimmu.2024.1360281

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Borch, Carri, Reynisson, Alvarez, Munk, Montemurro, Kristensen, Tvingsholm, Holm, Heeke, Moss, Hansen, Schaap-Johansen, Bagger, de Lima, Rohrberg, Funt, Donia, Svane, Lassen, Barra, Nielsen and Hadrup

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Data overview. (A) Data overview illustrating the number of validated peptides for each cohort and the number of patients screened together with a summary of the total amount validated with the number of immunogenic and non-immunogenic neopeptides. (B) General workflow of the data generation, including the patient samples being sequenced and patients’ specific libraries with neoepitope candidates being generated and screened with patients’ samples to find immunogenic neoepitopes. (C) Patient overview according to the number of neoepitopes screened (black dots), immunogenic neoepitopes (gray dots), and fraction immunogenic (red dots). MM, the melanoma cohort; mUC, the mUC cohort; RH, the basket trial cohort.